Search

Your search keyword '"Kuniko Ieda"' showing total 10 results
Start Over Author "Kuniko Ieda" Language undetermined
10 results on '"Kuniko Ieda"'

2. Pulmonary hypertension with bronchopulmonary dysplasia: Aichi cohort study

Author

Yuri Kawai, Masahiro Hayakawa, Taihei Tanaka, Yasumasa Yamada, Atsushi Nakayama, Yuichi Kato, Masanori Kouwaki, Takenori Kato, Ryo Tanaka, Kanji Muramatsu, Seiji Hayashi, Hikaru Yamamoto, Koji Takemoto, Kuniko Ieda, Yoshiaki Nagaya, Shigeru Honda, Osamu Shinohara, Yusuke Funato, Minoru Kokubo, Hiroki Imamine, and Masafumi Miyata

Subjects
Cohort Studies, Pregnancy, Hypertension, Pulmonary, Sepsis, Pediatrics, Perinatology and Child Health, Infant, Newborn, Humans, Infant, Female, Gestational Age, Oligohydramnios, Bronchopulmonary Dysplasia, Retrospective Studies
Abstract

The incidence of pulmonary hypertension (PH) associated with bronchopulmonary dysplasia (BPD) has not been investigated in regional cohorts. The aim of this study was to clarify the incidence of PH associated with BPD in all very low birthweight infants (VLBWIs) born during the study period in Aichi Prefecture, Japan.We conducted a retrospective observational cohort study of all VLBWIs born in Aichi Prefecture. The inclusion criteria were VLB, birth between 1 January 2015 and 31 December 2015, and admission to any neonatal intensive care unit in Aichi Prefecture. BPD28d and BPD36w were defined as the need for supplemental oxygen or any respiratory support at 28 days of age or 36 weeks of postmenstrual age (PMA). The primary outcome was the incidence of PH after 36 weeks' PMA (PH36w) in VLBWIs with BPD28d and BPD36w. The secondary outcomes were the clinical factors related to PH36w in BPD36w patients. Mann-Whitney U-test and Fisher's exact test were used for univariate analysis. Differences were considered statistically significant at P 0.05. Risk ratio (RR) and 95% confidence interval (CI) were also evaluated.A total of 441 patients were analyzed. A total of 217 and 131 patients met the definition of BPD28d and BPD36w, respectively. Nine patients were diagnosed with PH36w (4.2% and 6.9% of the BPD28d and BPD36w patients, respectively). The presence of oligohydramnios (RR, 2.71; 95% CI: 1.55-4.73, P = 0.014) and sepsis (RR, 3.62; 95% CI: 1.51-8.63, P = 0.025) was significant in the PH36w patients.The incidence of PH36w was 4.2% and 6.9% in the BPD28d and BPD36w patients, respectively. Oligohydramnios and sepsis were significantly associated with PH36w in VLBWIs.

Published
2022
Full Text
View/download PDF

3. Variations in Neonatal Length of Stay of Babies Born Extremely Preterm: An International Comparison Between iNeo Networks

Author

Sarah E. Seaton, Elizabeth S. Draper, Mark Adams, Satoshi Kusuda, Stellan Håkansson, Kjell Helenius, Brian Reichman, Liisa Lehtonen, Dirk Bassler, Shoo K. Lee, Maximo Vento, Brian A. Darlow, Franca Rusconi, Marc Beltempo, Tetsuya Isayama, Kei Lui, Mikael Norman, Junmin Yang, Prakesh S. Shah, Neena Modi, Peter Marshall, Peter Schmidt, Anjali Dhawan, Larissa Korostenski, Javeed Travadi Travadi, Mary Sharp, Andy Gill, Jane Pillow, Jacqueline Stack, Pita Birch, Karen Nothdurft, Lucy Cooke, Dan Casalaz, Jim Holberton, Alice Stewart, Lyn Downe, Michael Stewart, Andrew Berry, Rod Hunt, Peter Morris, Tony De Paoli, Srinivas Bolisetty, Mary Paradisis, Mark Greenhalgh, Pieter Koorts, Carl Kuschel, Sue Jacobs, Lex Doyle, John Craven, Andrew Numa, Hazel Carlisle, Nadia Badawi, Himanshu Popat, Guan Koh, Jonathan Davis, Melissa Luig, Bevan Headley, Chad Andersen, Linda Ng, Georgina Chambers, Nicola Austin, Adrienne Lynn, Brian Darlow, Liza Edmonds, Lindsay Mildenhall, Mariam Buksh, Malcolm Battin, Jutta van den Boom, Vaughan Richardson, David Barker, Barbara Hammond, Victor Samuel Rajadurai, Simon Lam, Genevieve Fung, Jaideep Kanungo, Joseph Ting, Zenon Cieslak, Rebecca Sherlock, Ayman Abou Mehrem, Jennifer Toye, Khalid Aziz, Carlos Fajardo, Jaya Bodani, Lannae Strueby, Mary Seshia, Deepak Louis, Ruben Alvaro, Amit Mukerji, Orlando Da Silva, Mohammad Adie, Kyong-Soon Lee, Eugene Ng, Brigitte Lemyre, Thierry Daboval, Faiza Khurshid, Ermelinda Pelausa, Keith Barrington, Anie Lapoint, Guillaume Ethier, Christine Drolet, Bruno Piedboeuf, Martine Claveau, Marie St-Hilaire, Valerie Bertelle, Edith Masse, Roderick Canning, Hala Makary, Cecil Ojah, Luis Monterrosa, Julie Emberley, Jehier Afifi, Andrzej Kajetanowicz, Marjo Metsäranta, Outi Tammela, Ulla Sankilampi, Timo Saarela, Iris Morag, Shmuel Zangen, Tatyana Smolkin, Francis Mimouni, David Bader, Avi Rothschild, Zipora Strauss, Clari Felszer, Hussam Omari, Smadar Even Tov-Friedman, Benjamin Bar-Oz, Michael Feldman, Nizar Saad, Orna Flidel-Rimon, Meir Weisbrod, Daniel Lubin, Ita Litmanovitz, Amir Kugelman, Eric Shinwell, Gil Klinger, Yousif Nijim, Alona Bin-Nun, Agneta Golan, Dror Mandel, Vered Fleisher-Sheffer, Anat Oron, Lev Bakhrakh, Satoshi Hattori, Masaru Shirai, Toru Ishioka, Toshihiko Mori, Takasuke Amizuka, Toru Huchimukai, Hiroshi Yoshida, Ayako Sasaki, Junichi Shimizu, Toshihiko Nakamura, Mami Maruyama, Hiroshi Matsumoto, Shinichi Hosokawa, Atsuko Taki, Machiko Nakagawa, Kyone Ko, Azusa Uozumi, Setsuko Nakata, Akira Shimazaki, Tatsuya Yoda, Osamu Numata, Hiroaki Imamura, Azusa Kobayashi, Shuko Tokuriki, Yasushi Uchida, Takahiro Arai, Mitsuhiro Ito, Kuniko Ieda, Toshiyuki Ono, Masashi Hayashi, Kanemasa Maki, MieToru Yamakawa, Masahiko Kawai, Noriko Fujii, Kozue Shiomi, Koji Nozaki, Hiroshi Wada, Taho Kim, Yasuyuki Tokunaga, Akihiro Takatera, Toshio Oshima, Hiroshi Sumida, Yae Michinomae, Yoshio Kusumoto, Seiji Yoshimoto, Takeshi Morisawa, Tamaki Ohashi, Yukihiro Takahashi, Moriharu Sugimoto, Noriaki Ono, Shinichiro Miyagawa, Takahiko Saijo, Takashi Yamagami, Kosuke Koyano, Shoko Kobayashi, Takeshi Kanda, Yoshihiro Sakemi, Mikio Aoki, Koichi Iida, Mitsushi Goshi, Yuko Maruyama, Alejandro Avila-Alvarez, José Luis Fernandez-Trisac, Ma Luz Couce Pico, María José Fernández Seara, Andrés Martínez Gutiérrez, Carolina Vizcaíno, Miriam Salvador Iglesias, Honorio Sánchez Zaplana, Belén Fernández Colomer, José Enrique García López, Rafael García Mozo, M. Teresa González Martínez, Ma Dolores Muro Sebastián, Marta Balart Carbonell, Joan Badia Barnusell, Mònica Domingo Puiggròs, Josep Figueras Aloy, Francesc Botet Mussons, Israel Anquela Sanz, Gemma Ginovart Galiana, W. Coroleu, Martin Iriondo, Laura Castells Vilella, Roser Porta, Xavier Demestre, Silvia Martínez Nadal, Cristina de Frutos Martínez, María Jesús López Cuesta, Dolores Esquivel Mora, Joaquín Ortiz Tardío, Isabel Benavente, Almudena Alonso, Ramón Aguilera Olmos, Miguel A. García Cabezas, Ma Dolores Martínez Jiménez, Ma Pilar Jaraba Caballero, Ma Dolores Ordoñez Díaz, Alberto Trujillo Fagundo, Lluis Mayol Canals, Fermín García-Muñoz Rodrigo, Lourdes Urquía Martí, María Fernanda Moreno Galdo, José Antonio Hurtado Suazo, Eduardo Narbona López, José Uberos Fernández, Miguel A. Cortajarena Altuna, Oihana Muga Zuriarrain, David Mora Navarro, María Teresa Domínguez, Ma Yolanda Ruiz del Prado, Inés Esteban Díez, María Teresa Palau Benavides, Santiago Lapeña, Teresa Prada, Eduard Soler Mir, Araceli Corredera Sánchez, Enrique Criado Vega, Náyade del Prado, Cristina Fernández, Lucía Cabanillas Vilaplana, Irene Cuadrado Pérez, Luisa López Gómez, Laura Domingo Comeche, Isabel Llana Martín, Carmen González Armengod, Carmen Muñoz Labián, Ma José Santos Muñoz, Dorotea Blanco Bravo, Vicente Pérez, Ma Dolores Elorza Fernández, Celia Díaz González, Susana Ares Segura, Manuela López Azorín, Ana Belén Jimenez, Tomás Sánchez-Tamayo, Elías Tapia Moreno, María González, José Enrique Sánchez Martínez, José María Lloreda García, Concepción Goñi Orayen, Javier Vilas González, María Suárez Albo, Eva González Colmenero, Elena Pilar Gutiérrez González, Beatriz Vacas del Arco, Josefina Márquez Fernández, Laura Acosta Gordillo, Mercedes Granero Asensio, Carmen Macías Díaz, Mar Albújar, Pedro Fuster Jorge, Sabina Romero, Mónica Rivero Falero, Ana Belén Escobar Izquierdo, Javier Estañ Capell, Ma Isabel Izquierdo Macián, Ma Mar Montejo Vicente, Raquel Izquierdo Caballero, Ma Mercedes Martínez, Aintzane Euba, Amaya Rodríguez Serna, Juan María López de Heredia Goya, Alberto Pérez Legorburu, Ana Gutiérrez Amorós, Víctor Manuel Marugán Isabel, Natalio Hernández González, Segundo Rite Gracia, Ma Purificación Ventura Faci, Ma Pilar Samper Villagrasa, Jiri Kofron, Katarina Strand Brodd, Andreas Odlind, Lars Alberg, Sofia Arwehed, Ola Hafström, Anna Kasemo, Karin Nederman, Lars Åhman, Fredrik Ingemarsson, Henrik Petersson, Pernilla Thurn, Eva Albinsson, Bo Selander, Thomas Abrahamsson, Ingela Heimdahl, Kristbjorg Sveinsdottir, Erik Wejryd, Anna Hedlund, Maria Katarina Söderberg, Lars Navér, Thomas Brune, Jens Bäckström, Johan Robinson, Aijaz Farooqi, Erik Normann, Magnus Fredriksson, Anders Palm, Urban Rosenqvist, Bengt Walde, Cecilia Hagman, Andreas Ohlin, Rein Florell, Agneta Smedsaas-Löfvenberg, Philipp Meyer, Rachel Kusche, Sven Schulzke, Mathias Nelle, Bendicht Wagner, Thomas Riedel, Grégoire Kaczala, Riccardo E. Pfister, Jean-François Tolsa, Matthias Roth, Martin Stocker, Bernhard Laubscher, Andreas Malzacher, John P. Micallef, Lukas Hegi, Romaine Arlettaz, Vera Bernet, Carlo Dani, Patrizio Fiorini, Paolo Ghirri, Barbara Tomasini, Anita Mittal, Jonathan Kefas, Anand Kamalanathan, Michael Grosdenier, Christopher Dewhurst, Andreea Bontea, Delyth Webb, Ross Garr, Ahmed Hassan, Priyadarshan Ambadkar, Mark Dyke, Katharine McDevitt, Glynis Rewitzky, Angela D'Amore, P. Kamath, Paul Settle, Natasha Maddock, Ngozi Edi-Osagie, Christos Zipitis, Carrie Heal, Jacqeline Birch, Abdul Hasib, Aung Soe, Bushra Abdul-Malik, Hamudi Kisat, Vimal Vasu, Savi Sivashankar, Richa Gupta, Chris Rawlingson, Tim Wickham, Marice Theron, Giles Kendall, Aashish Gupta, Narendra Aladangady, Imdad Ali, Neeraj Jain, Khalid Mannan, Vadivelam Murthy, Caroline Sullivan, Shu-Ling Chuang, Tristan Bate, Lidia Tyszcuzk, Geraint Lee, Ozioma Obi, John Chang, Vinay Pai, Charlotte Huddy, Salim Yasin, Richard Nicholl, Poornima Pandey, Jonathan Cusack, Venkatesh Kairamkonda, Dominic Muogbo, Liza Harry, Pinki Surana, Penny Broggio, Tilly Pillay, Sanjeev Deshpande, null Mahadevan, Alison Moore, Porus Bastani, Mehdi Garbash, Mithilesh Lal, Majd Abu-Harb, Alex Allwood, Michael Selter, Paul Munyard, David Bartle, Siba Paul, Graham Whincup, Sanghavi Rekha, Philip Amess, Ben Obi, Peter Reynolds, Indranil Misra, Peter De Halpert, Sanjay Salgia, Rekha Sanghavi, Nicola Paul, Abby Deketelaere, Minesh Khashu, Mark Johnson, Charlotte Groves, Jim Baird, Nick Brennan, Katia Vamvakiti, John McIntyre, Jennifer Holman, Stephen Jones, Alison Pike, Pamela Cairns, Megan Eaton, Karin Schwarz, David Gibson, Lawrence Miall, Dr Krishnamurthy, and Sankara Narayanan

Subjects
Male, medicine.medical_specialty, Birth weight, Standard score, Care provision, 03 medical and health sciences, 0302 clinical medicine, Sex Factors, Pregnancy, 030225 pediatrics, Intensive Care Units, Neonatal, Infant Mortality, Medicine, Humans, 030212 general & internal medicine, International network, business.industry, Obstetrics, Extremely preterm, Infant, Newborn, Gestational age, Infant, Length of Stay, medicine.disease, Infant mortality, Infant, Extremely Premature, Pediatrics, Perinatology and Child Health, Linear Models, Female, Pregnancy, Multiple, business
Abstract

Objective To compare length of stay (LOS) in neonatal care for babies born extremely preterm admitted to networks participating in the International Network for Evaluating Outcomes of Neonates (iNeo). Study design Data were extracted for babies admitted from 2014 to 2016 and born at 24 to 28 weeks of gestational age (n = 28 204). Median LOS was calculated for each network for babies who survived and those who died while in neonatal care. A linear regression model was used to investigate differences in LOS between networks after adjusting for gestational age, birth weight z score, sex, and multiplicity. A sensitivity analysis was conducted for babies who were discharged home directly. Results Observed median LOS for babies who survived was longest in Japan (107 days); this result persisted after adjustment (20.7 days more than reference, 95% CI 19.3-22.1). Finland had the shortest adjusted LOS (−4.8 days less than reference, 95% CI –7.3 to −2.3). For each week's increase in gestational age at birth, LOS decreased by 12.1 days (95% CI –12.3 to −11.9). Multiplicity and male sex predicted mean increases in LOS of 2.6 (95% CI 2.0-3.2) and 2.1 (95% CI 1.6-2.6) days, respectively. Conclusions We identified between-network differences in LOS of up to 3 weeks for babies born extremely preterm. Some of these may be partly explained by differences in mortality, but unexplained variations also may be related to differences in clinical care practices and healthcare systems between countries.

Published
2020

4. Palivizumab Prophylaxis in Preterm Infants and Subsequent Recurrent Wheezing. Six-Year Follow-up Study

Author

Hiroyuki Mochizuki, Satoshi Kusuda, Kenji Okada, Shigemi Yoshihara, Hiroyuki Furuya, Eric A. F. Simões, Hideomi Asanuma, Hiroshi Yoshida, Masahiko Katayose, Takashi Imamura, Hiroshi Suzumura, Youko Honma, Jichi Medical, Kenichi Maruyama, Yasushi Ohki, Koji Ozasa, Akiyoshi Nariai, Atsushi Uchiyama, Hideko Uryu, Shigeharu Hosono, Masatoshi Kondo, Yasuharu Kawase, Kazunari Ikeda, Atsushi Naito, Yuki Minami, Tomohiko Nakamura, Atsushi Baba, Yoshihisa Nagayama, Hisashi Kaneda, Shigeru Ohki, Masami Shiraii, Yuto Henmi, Chizuko Suzuki, Kuniko Ieda, Taihei Tanaka, Yoshinori Kono, Kashiro Nisizawa, Fusako Niwa, Hisato Ito, Yasuyuki Tokunaga, Yoshinobu Takada, Yoshihide Nishikawa, Ikuo Nagata, Yasuhisa Kajino, Shinichi Watabe, Hiroyuki Yoshio, Nobumasa Takahashi, Nobutaka Sasaki, Michiko Hayashidani, Hiroshi Tateishi, Kenji Matsushita, Masatoshi Nakamura, Hideki Nakayama, Go Yamamoto, Noriaki Kanemitsu, Toshimitsu Takayanagi, Ayumi Sato, and Satoshi Ibara

Subjects
Male, Pulmonary and Respiratory Medicine, Palivizumab, Pediatrics, medicine.medical_specialty, First year of life, Respiratory Syncytial Virus Infections, Disease, Critical Care and Intensive Care Medicine, Antiviral Agents, 03 medical and health sciences, 0302 clinical medicine, Recurrence, medicine, Humans, Prospective Studies, 030212 general & internal medicine, Child, Respiratory Sounds, Asthma, business.industry, Follow up studies, Infant, Gestational age, Medical practice, medicine.disease, Respiratory Syncytial Viruses, Treatment Outcome, 030228 respiratory system, Case-Control Studies, Child, Preschool, Female, Observational study, business, Infant, Premature, Follow-Up Studies, medicine.drug
Abstract

Respiratory syncytial virus (RSV) induces not only infantile recurrent wheezing but also potentially atopic asthma.To test the effect of RSV infection on development of subsequent atopic asthma, we evaluated whether palivizumab, an anti-RSV monoclonal antibody, by preventing severe RSV disease in the first year of life, could impact subsequent recurrent wheezing and atopic asthma at 6 years of age.During the 2007 to 2008 RSV season, the decision to administer palivizumab was made based on standard medical practice and an observational prospective multicenter (n = 52) case-control study in preterm infants with a gestational age between 33 and 35 weeks followed from 0 to 3 years (preceding Committee on Recurrent Wheezing study). The 52 investigators at hospitals then followed these subjects until 6 years of age, reported here (Effects of Preventive Treatment for Respiratory Syncytial [RS] Virus Infection During Infancy on Later Atopic Asthma in Preterm Infants; Scientific Committee for Elucidation of Infantile Asthma). Parents of study subjects reported the infants' physicians' assessment of recurrent wheezing, using a report card and a novel mobile phone-based reporting system using the Internet. The primary endpoint was the incidence of atopic asthma.Of 444 preterm infants enrolled, 349 received palivizumab during the first year of life. At 6 years, atopic asthma was not different in the groups: 15.3 and 18.2% of infants in the treated and untreated groups, respectively (P = 0.57). On the other hand, physician-diagnosed recurrent wheezing was observed in 15.3 and 31.6% in the treated and untreated groups, respectively (P = 0.003).Palivizumab prophylaxis administered to preterm infants did not suppress the onset of atopic asthma but resulted in a significantly lower incidence of recurrent wheezing during the first 6 years. Clinical trial registered with www.clinicaltrials.gov (NCT 01545245).

Published
2017
Full Text
View/download PDF

5. Neonatal Intensive Care Unit-Level Patent Ductus Arteriosus Treatment Rates and Outcomes in Infants Born Extremely Preterm

Author

Mikael Norman, Anne Synnes, Toshihiko Mori, Mitsuhiro Ito, David Kohelet, Hiroshi Matsumoto, Luis Monterrosa, Philipp Meyer, Akhil Deshpandey, Pernilla Thurn, Hiroaki Imamura, Edith Masse, Yuko Maruyama, Toru Ishioka, Satoshi Hattori, Ola Hafström, Wendy Yee, Koravangattu Sankaran, Rachel Kusche, Jehier Afifi, Zipora Strauss, Shmuel Zangen, Takeshi Kanda, Mie Toru Yamakawa, Takashi Yamagami, Sven M. Schulzke, Daniel Lubin, Gil Klinger, Mark Raymond Adams, Maria Katarina Söderberg, Fredrik Ingemarsson, Jennifer Toye, Yukihiro Takahashi, Junichi Shimizu, Michael Feldman, Vera Bernet, Marc Beltempo, Adele Harrison, Joseph Ting, Takeshi Morisawa, Kimberly Dow, Atsuko Taki, Meir Weisbrod, Prakesh S. Shah, Keith J. Barrington, Brian Reichman, Ulla Sankilampi, Benjamin Bar-Oz, Mary Seshia, John P. Micallef, Lev Bakhrakh, Hussam Omari, Liisa Lehtonen, Amit Mukerji, Kozue Shiomi, Bernhard Laubscher, Mikio Aoki, Hiroshi Wada, Cecil Ojah, Dror Mandel, Martin Stocker, Ingela Heimdahl, Toshio Oshima, Bo Selander, Rebecca Sherlock, Yousif Nijim, Ita Litmanovitz, Yoshihiro Sakemi, Yoshio Kusumoto, Henrik Petersson, Alona Bin-Nun, Christine Drolet, Shoko Kobayashi, Shinichiro Miyagawa, Kyong-Soon Lee, Urban Rosenqvist, Takasuke Amizuka, Jean-François Tolsa, Hiroshi Yoshida, Martine Claveau, Andreas Malzacher, Akihiro Takatera, Hiroshi Sumida, Agneta Golan, Jens Bäckström, Thomas Riedel, Rein Florell, Masahiko Kawai, Thomas Brune, Osamu Numata, Lars Åhman, Stellan Håkansson, Outi Tammela, Thomas Abrahamsson, Brigitte Lemyre, Michael Dunn, Clari Felszer, Shuko Tokuriki, Valerie Bertelle, Cecilia Hagman, Takahiko Saijo, Eli Heymann, Akira Shimazaki, Andreas Odlind, Sibasis Daspal, Kosuke Koyano, Roderick Canning, Kjell Helenius, Machiko Nakagawa, Yasushi Uchida, Tamaki Ohashi, Kanemasa Maki, Carlos Fajardo, Orlando da Silva, Matthias Roth, Romaine Arlettaz, Yasuyuki Tokunaga, Toshihiko Nakamura, Azusa Uozumi, Azusa Kobayashi, Avi Rothschild, Karin Nederman, Chuks Nwaesei, Anna Hedlund, Setsuko Nakata, Andreas Ohlin, Katarina Strand Brodd, Erik Normann, Amir Kugelman, Bengt Walde, Dirk Bassler, Tatyana Smolkin, Bruno Piedboeuf, Ermelinda Pelausa, Shoo K. Lee, Noriko Fujii, Orna Flidel-Rimon, Hala Makary, Jiri Kofron, Aijaz Farooqi, Taho Kim, Lars Navér, Khalid Aziz, Toru Huchimukai, Vered Fleisher-Sheffer, Tatsuya Yoda, Agneta Smedsaas Löfvenberg, Tetsuya Isayama, Noriaki Ono, Eva Albinsson, Ruben Alvaro, Kristbjorg Sveinsdottir, Anna Kasemo, Grégoire Kaczala, Junmin Yang, Kyone Ko, Zenon Cieslak, Timo Saarela, Sofia Arwehed, Bendicht Peter Wagner, Mami Maruyama, Eric S. Shinwell, Lars Alberg, Mitsushi Goshi, Zarin Kalapesi, Amish Jain, Moriharu Sugimoto, Mathias Nelle, Koji Nozaki, Kuniko Ieda, Shinichi Hosokawa, Smadar Even Tov-Friedman, Masashi Hayashi, Magnus Fredriksson, Lukas Hegi, Nizar Saad, Seiji Yoshimoto, Francis B. Mimouni, David Bader, Yae Michinomae, Johan Robinson, Erik Wejryd, Toshiyuki Ono, Sture Andersson, Satoshi Kusuda, Ayako Sasaki, Takahiro Arai, Koichi Iida, Masaru Shirai, Andrzej Kajetanowicz, Riccardo Pfister, Anders Palm, and Pfister, Riccardo

Subjects
Male, Pediatrics, Neonatal intensive care unit, health care facilities, manpower, and services, Indomethacin, Anti-Inflammatory Agents, Ibuprofen, Ibuprofen/therapeutic use, Cohort Studies, 0302 clinical medicine, Japan, Periventricular/epidemiology, Neonatal, Ductus arteriosus, 030212 general & internal medicine, Israel, Ductus Arteriosus, Patent, ddc:618, Anti-Inflammatory Agents, Non-Steroidal, Composite outcomes, 3. Good health, Japan/epidemiology, Europe, Intensive Care Units, medicine.anatomical_structure, Echocardiography, Infant, Extremely Premature, Cohort, cardiovascular system, Necrotizing/epidemiology, Gestation, Female, Cohort study, Adult, Non-Steroidal/therapeutic use, Canada, congenital, hereditary, and neonatal diseases and abnormalities, medicine.medical_specialty, Leukomalacia, Periventricular, Birth weight, education, Canada/epidemiology, Extremely Premature, Europe/epidemiology, 03 medical and health sciences, Indomethacin/therapeutic use, Enterocolitis, Necrotizing, Intensive Care Units, Neonatal, 030225 pediatrics, medicine, Humans, cardiovascular diseases, Israel/epidemiology, Cerebral Intraventricular Hemorrhage, Retrospective Studies, Cerebral Intraventricular Hemorrhage/epidemiology, Cardiovascular Surgical Procedures/statistics & numerical data, Enterocolitis, business.industry, Cardiovascular Surgical Procedures, Extremely preterm, Infant, Newborn, Infant, Ductus Arteriosus, Newborn, Pediatrics, Perinatology and Child Health, Linear Models, Patent/diagnostic imaging/epidemiology/therapy, business, Leukomalacia
Abstract

To assess associations between neonatal intensive care unit (NICU)-level patent ductus arteriosus (PDA) treatment rates (pharmacologic or surgical) and neonatal outcomes.This cohort study included infants born at 24-28 weeks of gestation and birth weight1500 g in 2007-2015 in NICUs caring for ≥100 eligible infants in 6 countries. The ratio of observed/expected (O/E) PDA treatment rates was derived for each NICU by estimating the expected rate using a logistic regression model adjusted for potential confounders and network. The primary composite outcome was death or severe neurologic injury (grades III-IV intraventricular hemorrhage or periventricular leukomalacia). The associations between the NICU-level O/E PDA treatment ratio and neonatal outcomes were assessed using linear regression analyses including a quadratic effect (a square term) of the O/E PDA treatment ratio.From 139 NICUs, 39 096 infants were included. The overall PDA treatment rate was 45% in the cohort (13%-77% by NICU) and the O/E PDA treatment ratio ranged from 0.30 to 2.14. The relationship between the O/E PDA treatment ratio and primary composite outcome was U-shaped, with the nadir at a ratio of 1.13 and a significant quadratic effect (P.001). U-shaped relationships were also identified with death, severe neurologic injury, and necrotizing enterocolitis.Both low and high PDA treatment rates were associated with death or severe neurologic injury, whereas a moderate approach was associated with optimal outcomes.

Published
2020
Full Text
View/download PDF

6. Prognostic factors of hydrops fetalis with pleural effusion

Author

Koji Takemoto, Osamu Shinohara, Yasuhiro Wakano, Kuniko Ieda, Masafumi Miyata, Seiji Hayashi, Tetsuo Hattori, Masanori Kouwaki, Masahiro Hayakawa, Taihei Tanaka, Kyoko Yokoi, Hikaru Yamamoto, Shigeru Honda, Makoto Oshiro, Takenori Kato, Yasumasa Yamada, Atsushi Nakayama, and Minoru Kokubo

Subjects
Male, medicine.medical_specialty, Pleural effusion, Birth weight, Hydrops Fetalis, Gestational Age, Infant, Premature, Diseases, Severity of Illness Index, 03 medical and health sciences, 0302 clinical medicine, Hydrops fetalis, Severity of illness, medicine, Humans, 030212 general & internal medicine, Survival rate, Retrospective Studies, 030219 obstetrics & reproductive medicine, Obstetrics, business.industry, Infant, Newborn, Gestational age, Retrospective cohort study, medicine.disease, Prognosis, Pleural Effusion, Survival Rate, Logistic Models, Pediatrics, Perinatology and Child Health, Multivariate Analysis, Gestation, Female, business, Infant, Premature
Abstract

Background Hydrops fetalis (HF) has low survival rate, particularly in cases of preterm birth. In addition, the severity index of HF has not been fully investigated yet. This study was aimed to clarify the prognostic factors of HF patients with pleural effusion. Methods All live-born HF patients with pleural effusion, except for chromosomal abnormality or complex congenital heart disease, born from 2009 to 2013 in Aichi Prefecture in Japan were included. The prenatal, perinatal, and postnatal information was obtained from their medical records and was retrospectively analyzed. Results Forty-one HF patients with pleural effusion were included, and twenty-eight patients (68%) survived. The multivariate logistic stepwise analysis revealed that the gestational birth week (OR 0.71, 95% CI 0.52–0.96, p = 0.027) and standard deviation (SD) score of the birth weight (OR 1.74, 95% CI 1.01–2.99, p = 0.045) were significant factors for postnatal death. All patients with both >32 gestational weeks and

Published
2017

7. Factors related to home health-care transition in trisomy 13

Author

Kuniko Ieda, Yuichi Kato, Eiko Kato, Yoshiaki Sato, Yuma Kitase, Yukako Muramatsu, Reina Hyodo, Masahiro Hayakawa, Seiji Hayashi, Taiki Kondo, Tetsuo Hattori, Masatoki Ito, Takashi Tachibana, Makoto Oshiro, and Akiko Saito

Subjects
0301 basic medicine, Adult, Male, Pediatrics, medicine.medical_specialty, Trisomy 13 Syndrome, Birth weight, Gestational Age, 030105 genetics & heredity, Standard score, 03 medical and health sciences, Home health, Genetics, Medicine, Birth Weight, Humans, In patient, Genetics (clinical), Retrospective Studies, Chromosomes, Human, Pair 13, business.industry, Infant, Newborn, Gestational age, Care group, medicine.disease, Prognosis, Home Care Services, Hospitalization, Survival Rate, Treatment strategy, Female, business, Trisomy
Abstract

Trisomy 13 (T13) is accompanied by severe complications, and it can be challenging to achieve long-term survival without aggressive treatment. However, recently, some patients with T13 have been receiving home care. We conducted this study to investigate factors related to home health-care transition for patients with T13.We studied 28 patients with T13 born between January 2000 and December 2014. We retrospectively compared nine home care transition patients (the home care group) and 19 patients that died during hospitalization (the discharge at death group). The median gestational age of the patients was 36.6 weeks, with a median birth weight of 2,047 g. Currently, three patients (11%) have survived, and 25 (89%) have died. The home care group exhibited a significantly longer gestational age (38.9 vs. 36.3 weeks, p = 0.039) and significantly larger occipitofrontal circumference Z score (-0.04 vs. -0.09, p = 0.019). Congenital heart defects (CHD) was more frequent in the discharge at death group, with six patients in the home care group and 18 patients in the discharge at death group (67% vs. 95%, p = 0.047), respectively. Survival time was significantly longer in the home care group than in the discharge at death group (171 vs. 19 days, p = 0.012). This study has shown that gestational age, occipitofrontal circumference Z score at birth, and the presence of CHD are helpful prognostic factors for determining treatment strategy in patients with T13.

Published
2016

8. Carbohydrate and Energy Metabolism in the Brain of Rats With Thromboxane A2-Induced Fetal Growth Restriction

Author

Hikaru Yamamoto, Tetsuo Hattori, Atsushi Nakayama, Yuko Ichinohashi, Kuniko Ieda, Masahiro Hayakawa, Seiji Kojima, Hayato Hemmi, Miharu Ito, and Yoshiaki Sato

Subjects
medicine.medical_specialty, Central nervous system, Gestational Age, Carbohydrate metabolism, Biology, Fetal Hypoxia, Phosphocreatine, Rats, Sprague-Dawley, Thromboxane A2, chemistry.chemical_compound, Pregnancy, Internal medicine, medicine, Animals, Placental Circulation, Fetus, Fetal Growth Retardation, Glycogen, Cesarean Section, Gluconeogenesis, Brain, Organ Size, Carbohydrate, Rats, Disease Models, Animal, Endocrinology, medicine.anatomical_structure, Fetal Weight, chemistry, Pediatrics, Perinatology and Child Health, Carbohydrate Metabolism, Female, Energy Metabolism
Abstract

Fetal growth restriction (FGR) remains a cause of perinatal brain injury, sometimes leading to neurological and intellectual impairment. Although the mechanisms and pathophysiology of CNS injuries have not been elucidated completely, it is possible carbohydrate and energy metabolism may have an important role in the FGR brain. In this study, FGR was induced in rats by administration of synthetic thromboxane A2 (STA2). Pups were delivered by cesarean section. After killing, samples were obtained from the fetuses of both control and FGR rats for evaluation of carbohydrate and energy metabolism in brain tissue. Lactate and pyruvate levels in brain were reduced significantly in the FGR group. Glucose content in brain tissue tended to be increased in the FGR group. In contrast, glycogen content in brain tissue tended to be lower in the FGR group. However, these differences in glucose and glycogen content did not reach statistical significance. Brain high-energy reserves, including ATP, ADP, AMP, and phosphocreatine (P-Cr), were similar in the control and FGR groups. Gluconeogenesis compensated for chronic fetal hypoxia and decreased glycogen storage. Energy metabolism in the FGR brain is likely to be disrupted as a consequence of lower reserves of energy substrates.

Published
2011
Full Text
View/download PDF

9. An Animal Model of Intrauterine Growth Retardation Induced by Synthetic Thromboxane A2

Author

Yoshiaki Sato, Akiko Saito, Masayuki Hasegawa, Masahiro Hayakawa, Atsushi Nakayama, Koji Takemoto, Kuniko Ieda, and Shunji Mimura

Subjects
medicine.medical_specialty, Biology, Preeclampsia, Fetal Development, Rats, Sprague-Dawley, Thromboxane A2, 03 medical and health sciences, chemistry.chemical_compound, 0302 clinical medicine, Pregnancy, Weight loss, Internal medicine, medicine, Animals, Infusions, Parenteral, reproductive and urinary physiology, Fetus, Fetal Growth Retardation, 030219 obstetrics & reproductive medicine, Obstetrics and Gynecology, medicine.disease, Pathophysiology, Rats, Disease Models, Animal, Endocrinology, chemistry, Forebrain, Gestation, Female, medicine.symptom, 030217 neurology & neurosurgery
Abstract

Intrauterine growth retardation (IUGR) is an important cause of prenatal and neonatal morbidity, and neurologic abnormalities. Although several animal models of IUGR have been developed for scientific investigation, few models approximate the pathophysiology in human fetal growth failure resulting from pregnancy-induced hypertension and preeclampsia. We developed an animal model of IUGR in which fetal growth restriction was induced by administering a synthetic thromboxane A(2) analogue (STA(2)) to the mother.Timed pregnant Sprague-Dawley rats were used in this study. STA(2) was delivered into the peritoneal cavity of the pregnant female at a rate of 20 ng/h from day 13 of pregnancy. The effectiveness of this model was evaluated by monitoring the overall growth of the fetuses and neonates and measuring the weight and biochemical composition of individual organs.Fetuses and neonates from the STA(2) group showed a highly significant weight reduction throughout the observation period from day 19 of gestation to postnatal day 7. Weight reduction near and at term exceeded 10% and became more pronounced during the first week after birth. Fetuses on the 20th gestational day exhibited a pattern of growth retardation characteristic of asymmetrical IUGR in which the weight reduction was prominent in the liver with relative sparing of the brain. However, the decrease in brain weight was more than 10%. The protein, DNA, and RNA contents of the liver were lower in the STA(2) group. The protein content of the forebrain and brainstem also decreased significantly in the STA(2) group compared with the control; however, the DNA content of the forebrain was higher in the STA(2) group.This animal model may mimic human IUGR more closely than previous models because the growth restriction is induced in a truly chronic manner.

Published
2006
Full Text
View/download PDF

10. Identification of novel FATP4 mutations in a Japanese patient with ichthyosis prematurity syndrome

Author

Masashi Morishita, Tamae Ohye, Makiko Tsutsumi, Ikuya Tsuge, Hidehito Inagaki, Chisato Inuo, Kuniko Ieda, Takema Kato, Kazuo Yamawaki, Hiroki Kurahashi, Akinori Hayakawa, and Yuji Mori

Subjects
Asian origin, Genetics, Carrier signal, medicine.medical_specialty, education.field_of_study, business.industry, Population, Heterozygote advantage, Atopic diathesis, Compound heterozygosity, medicine.disease, Biochemistry, Dermatology, medicine, Data Report, Ichthyosis prematurity syndrome, education, business, Molecular Biology
Abstract

Ichthyosis prematurity syndrome (IPS) is a rare autosomal recessive disorder characterized by prematurity, a thick caseous scale at birth and lifelong atopic diathesis. Here, we describe the first Japanese case of IPS and report novel compound heterozygous mutations (p.C403Y and p.R510H) in fatty acid transport protein 4 (FATP4). She is the first reported patient of Asian origin, entirely distinct from the Scandinavian population, in whom the heterozygote carrier frequency is very high.

Published
2014

Catalog

Books, media, physical & digital resources
See catalog results